<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Michael</forename><surname>Thomas</surname></persName>
							<email>michael.thomas@med.uni-heidelberg.de</email>
							<affiliation key="aff1">
								<orgName type="department">Dept of Thoracic Oncology</orgName>
								<orgName type="institution">Thoraxklinik im Universitätsklinikum Heidelberg</orgName>
								<address>
									<settlement>Thoraxklinik</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<orgName type="institution">Translational Lung Research Center Heidelberg (TLRC-H)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jürgen</forename><surname>Fischer</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Med. Clinic II, Oncology</orgName>
								<orgName type="institution">Klinik Löwenstein</orgName>
								<address>
									<settlement>Löwenstein</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Andreas</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Lungenfachklinik Immenhausen</orgName>
								<address>
									<settlement>Immenhausen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Dept of Pneumology</orgName>
								<orgName type="institution">Universitätsmedizin Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cornelius</forename><surname>Kortsik</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Katholisches Klinikum Mainz</orgName>
								<address>
									<settlement>Pneumology, Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Grah</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Pneumology and Lung Cancer Center</orgName>
								<orgName type="institution">Gemeinschaftskrankenhaus Havelhöhe</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Monika</forename><surname>Serke</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Pneumology/Oncology</orgName>
								<orgName type="institution">Lungenklinik Hemer</orgName>
								<address>
									<settlement>Hemer</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Von Eiff</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Internal Medicine</orgName>
								<orgName type="institution">Malteser Krankenhaus St Hildegardis</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Witt</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Dept of Pneumological Oncology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><surname>Kollmeier</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Lungenklinik Heckershorn</orgName>
								<orgName type="institution" key="instit2">HELIOS Klinikum Emil von Behring</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ernst</forename><surname>Müller</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<orgName type="laboratory">Airway Research Center North (ARCN)</orgName>
								<orgName type="institution">Forschungszentrum Borstel</orgName>
								<address>
									<addrLine>Medizinische Klinik</addrLine>
									<settlement>Borstel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Schenk</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Clinic for Oncology and Hematology</orgName>
								<orgName type="institution">Krankenhaus Barmherzige Brüder Regensburg</orgName>
								<address>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Schröder</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Hematology/ Oncology</orgName>
								<orgName type="institution">HELIOS St Johannes Klinik</orgName>
								<address>
									<settlement>Duisburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Villalobos</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Dept of Thoracic Oncology</orgName>
								<orgName type="institution">Thoraxklinik im Universitätsklinikum Heidelberg</orgName>
								<address>
									<settlement>Thoraxklinik</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<orgName type="institution">Translational Lung Research Center Heidelberg (TLRC-H)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Niels</forename><surname>Reinmuth</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Dept of Thoracic Oncology</orgName>
								<orgName type="institution">Thoraxklinik im Universitätsklinikum Heidelberg</orgName>
								<address>
									<settlement>Thoraxklinik</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<orgName type="institution">Translational Lung Research Center Heidelberg (TLRC-H)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<orgName type="laboratory" key="lab1">Lungenclinic Großhansdorf</orgName>
								<orgName type="laboratory" key="lab2">Airway Research Center North (ARCN)</orgName>
								<address>
									<settlement>Großhansdorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roland</forename><surname>Penzel</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Dept of Pathology</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Schnabel</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Dept of Pathology</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Acker</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Coordinating Center for Clinical Trials</orgName>
								<orgName type="institution">University of Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Reuss</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Coordinating Center for Clinical Trials</orgName>
								<orgName type="institution">University of Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Wolf</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Hematology/Oncology</orgName>
								<orgName type="institution" key="instit1">Med. Clinic IV</orgName>
								<orgName type="institution" key="instit2">Klinikum Kassel</orgName>
								<address>
									<settlement>Kassel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="laboratory">ABC-Lung Cancer Group</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department">Dept of Thoracic Oncology</orgName>
								<orgName type="institution">Thoraxklinik im Universitätsklinikum Heidelberg</orgName>
								<address>
									<settlement>Thoraxklinik</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<orgName type="institution">Translational Lung Research Center Heidelberg (TLRC-H)</orgName>
								<address>
									<addrLine>Amalienstrasse 5</addrLine>
									<postCode>69126</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">620E18C333DDD62D07BB58D0328204AC</idno>
					<idno type="DOI">10.1183/09031936.00021315]</idno>
					<note type="submission">Received: Dec 14 2014 | Accepted after revision: Jan 27 2015 | First published online: March 18 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:47+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC).</s><s>The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination compared to cisplatin, gemcitabine and bevacizumab.</s></p><p><s>Stage IIIB/IV patients with NS-NSCLC were randomised on erlotinib (150 mg daily) and bevacizumab (15 mg•kg −1 on day 1, every 3 weeks) (EB) until progression, or cisplatin (80 mg•m −2 on day 1, every 3 weeks) and gemcitabine (1250 mg•m −2 on days 1 and 8, every 3 weeks) up to six cycles and bevacizumab (15 mg•kg −1 on day 1, every 3 weeks) (PGB) until progression.</s></p><p><s>224 patients were randomised (EB n=111, PGB n=113).</s><s>The response rate (12% versus 36%; p&lt;0.0001), progression-free survival (median 3.5 versus 6.9 months; hazard ratio (HR) 1.85, 95% CI 1.39-2.45;</s><s>p&lt;0.0001) and overall survival (median 12.6 versus 17.8 months; HR 1.41, 95% CI 1.01-1.97;</s><s>p=0.04) clearly favoured PGB.</s><s>In patients with epidermal growth factor receptor mutations (n=32), response rate, progression-free survival and overall survival were not superior with EB.</s></p><p><s>Platinum-based combination chemotherapy remains the standard of care in first-line treatment of unselected NS-NSCLC.</s><s>Molecular targeted approaches strongly mandate appropriate testing and patient selection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>@ERSpublications</head><p><s>Platinum-based combination chemotherapy remains the standard of care in first-line treatment of unselected NS-NSCLC http://ow.ly/ITkNj</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The standard of care for unselected patients with advanced nonsmall cell lung cancer (NSCLC) is platinum-based combination chemotherapy <ref type="bibr" target="#b0">[1]</ref>.</s><s>Achievements with chemotherapy are modest and have reached an efficacy plateau envisaging a range of median survival of 8-11 months <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>In nonsquamous NSCLC (NS-NSCLC) further improvements were reported with the addition of bevacizumab to chemotherapy and continuation until disease progression <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>Preclinical data showed that this anti-vascular endothelial growth factor (anti-VEGF) strategy might be enhanced in terms of additive anti-tumour effects with an anti-epidermal growth factor receptor (EGFR) therapy <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s>Based on these observations, a phase I/II trial with erlotinib and bevacizumab in advanced NS-NSCLC after failure of at least one platinum-based treatment regimen showed promising results in unselected patients with adenocarcinoma: a 20% response rate, a median progression-free survival (PFS) of 6.2 months and a median overall survival of 12.6 months <ref type="bibr" target="#b7">[8]</ref>.</s><s>The current trial assessed the impact of this regimen in first-line treatment, in a randomised phase II setting.</s><s>To facilitate a descriptive comparison to an at best first-line approach, we chose cisplatin, gemcitabine and bevacizumab as the comparator for the following reasons.</s><s>1) As reflected by the CISCA (Cisplatin versus Carboplatin) meta-analysis, a cisplatinum-based regimen is considered the choice of priority in first-line treatment, in patients who are amenable <ref type="bibr" target="#b8">[9]</ref>.</s><s>2) At the time when the trial was designed, one of the best survival times from a phase III trial was derived from the Eastern Cooperative Oncology Group (ECOG) 4599 study (median 12.3 months) with carboplatin, paclitaxel and bevacizumab in NS-NSCLC <ref type="bibr" target="#b3">[4]</ref>.</s><s>Thus, bevacizumab was integrated in the comparator arm.</s></p><p><s>3) To resemble the treatment backbone of the AVAiL (Avastin in Lung) trial, gemcitabine was selected as a combination partner to cisplatin <ref type="bibr" target="#b9">[10]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>INNOVATIONS (Inoperable NS-NSCLC (stage IIIB/IV): a randomised phase II study with bevacizumab plus erlotinib or gemcitabine/cisplatin plus bevacizumab) was a multicentre open-label randomised phase II trial conducted in Germany.</s><s>Eligibility criteria included: histologically proven predominately NS-NSCLC; stage IIIB with pleural or cardiac effusion and no need for intervention or stage IV (6th Union for International Cancer Control staging classification); measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; age 18-75 years; ECOG performance status 0-2; adequate bone marrow, hepatic and renal function, defined as haemoglobin ⩾10.0 g•dL −1 , white blood cell count ⩾3.0×10 9 cells•L −1 , neutrophils ⩾1.5×10 9 cells•L −1 , platelets ⩾100×10 9 cells•L −1 , serum creatinine ⩽1.5 mg•dL −1 , estimated creatinine clearance ⩾60 mL•min −1 , serum bilirubin ⩽2.0 mg•dL −1 , aspartate aminotransferase and alkaline phosphatases ⩽5× upper limit of normal (ULN) with liver metastases and ⩽2.5× ULN without liver metastases; life expectancy of ⩾3 months; written informed consent provided.</s><s>Patients were excluded if contraindications existed for the use of bevacizumab, erlotinib, cisplatin or gemcitabine according to the official label.</s><s>The study was approved by the ethics committee of each participating institution and the German regulatory institute Paul Ehrlich.</s><s>An independent data safety monitoring board (DSMB), reviewing all serious adverse events, was nominated by the steering committee.</s><s>The DSMB reviewed the study performance at regular intervals.</s><s>When unfavourable results emerged in the TASK trial (a study of tarceva (erlotinib) in combination with avastin (bevacizumab) in patients with advanced NSCLC) <ref type="bibr" target="#b10">[11]</ref>, which used similar comparators, the DSMB reviewed current, interim efficacy data from the INNOVATIONS trial and indicated no reason to stop the trial.</s><s>The study was conducted in accordance with the Declaration of Helsinki (version 1996) and the applicable ICH-GCP (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Good Clinical Practice) guidelines.</s><s>It was registered on ClinicalTrials.gov</s><s>as NCT00536640 (EUDRA-CT 2006-004865-32).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Random assignment</head><p><s>Patients were centrally randomly assigned to one of the two treatment arms via fax registration by the Coordinating Center for Clinical Trials at the University of Marburg (Marburg, Germany).</s><s>Stratification parameters were ECOG performance status (0-1 versus 2), sex, smoking status (smoker versus nonsmoker) and institution.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatments</head><p><s>Patients randomly assigned to the experimental arm received erlotinib 150 mg daily and bevacizumab 15 mg•kg −1 body weight on day 1, every 3 weeks until disease progression (EB treatment arm).</s><s>After progression a switch to a combination chemotherapy of cisplatin 80 mg•m −2 on day 1 and gemcitabine 1250 mg•m −2 on days 1 and 8, every 3 weeks for a maximum of six cycles was recommended.</s><s>Patients randomly assigned to the standard treatment arm received cisplatin, gemcitabine and bevacizumab as outlined, for a maximum of six cycles (PGB treatment arm).</s><s>Patients with complete response, partial response or no change subsequently received bevacizumab maintenance therapy until disease progression.</s><s>Patients with progressive disease were recommended to switch to erlotinib 150 mg daily.</s></p><p><s>In cases with grade 3 or 4 toxicities (CTCAE (Common Terminology Criteria for Adverse Events) version 3.0), erlotinib could be reduced, stepping down in two dose levels (100 mg followed by 50 mg) with the possibility of interrupting treatment for a maximum of 2 weeks.</s><s>Bevacizumab could be interrupted in cases of uncontrolled hypertension or substantial proteinuria (&gt;2000 mg•day −1 ) for a maximum of 6 weeks.</s><s>Reinstitution was allowed after recovery from these symptoms.</s><s>Bevacizumab was terminated in cases of thromboembolic or bleeding events, haemoptysis or any other grade 3 or 4 toxicity (CTCAE version 3.0).</s><s>If chemotherapy resulted in a grade IV leuko-or thrombocytopenia (CTCAE), gemcitabine was reduced to 1000 mg•m −2 .</s><s>Nephrotoxicity with a dropping creatinine clearance in the range of 40-60 mL•min −1 demanded reduction of cisplatin down to 50% of the recommended dose; when dropping below 40 mL•min −1 , systemic treatment was stopped.</s><s>Impairment of hearing resulted in a switch of cisplatin to carboplatin (carboplatin dosage based on area under the curve 5 mg•mL −1 •min).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment procedures</head><p><s>Patients were evaluated at baseline with a complete history and physical examination, routine haematology and biochemistry, chest radiography, computed tomography (CT) scans of the chest and the abdomen, CT scan or magnetic resonance imaging of the brain, and a bone scan.</s><s>Blood cell examination was performed weekly during the treatment.</s><s>Complete haematology and biochemistry controls were performed every 3 weeks.</s><s>Examination of tumour response was performed every 6 weeks by CT scans of the chest and abdomen.</s><s>Other metastatic sites were assessed as appropriate.</s><s>The 6-week intervals of control investigations were maintained until disease progression.</s><s>Objective response was determined using RECIST.</s><s>Toxicity was graded according to CTCAE version 3.0 and coded according to the Medical Dictionary for Regulatory Activities.</s><s>Serious adverse events had to be reported immediately.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EGFR mutation analysis</head><p><s>For mutational analysis of EGFR (exons 19 and 21), serial sections from paraffin blocks of each case were cut.</s><s>The first section was stained with haematoxylin and eosin for the evaluation of the tumour region and tumour cell content by an experienced pathologist <ref type="bibr" target="#b11">[12]</ref>.</s><s>From the corresponding unstained serial sections, the marked tumour areas were manually microdissected and further processed to fully automated DNA extraction from the proteinase K digested tissues using a QIASymphony SP (Qiagen, Hilden, Germany).</s><s>Sanger sequencing-based mutation analysis was essentially performed as previously described <ref type="bibr" target="#b12">[13]</ref>.</s><s>In brief, for PCR amplification of EGFR, the following primers were used: 5′-gctggtaacatccacccaga-3′ (exon 19 forward), 5′-gagaaaaggtgggcctgag-3′ (exon 19 reverse), 5′-cctcacagcagggtcttctc-3′ (exon 21 forward) and 5′-cctggtgtcaggaaaatgct-3′ (exon 21 reverse).</s><s>Exons 2 and 3 of KRAS were amplified with the following primers: 5′-gtgtgacatgttctaatatagtca-3′ (exon 2 forward), 5′-gaatggtcctgcaccagtaa-3′ (exon 2 reverse), 5′-ccagactgtgtttctcccttc-3′ (exon 3 forward) and 5′ aacccacctataatggtg aatatct-3′ (exon 3 reverse).</s><s>Direct sequencing of the PCR amplicons was carried out for both strands on an 3500 Genetic Analyzer (Applied Biosystems by Life Technologies Corporation) using the BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems by Life Technologies Corporation).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>The sample size calculation was based on median PFS of 6.4 months, as reported in ECOG 4599 <ref type="bibr" target="#b3">[4]</ref>.</s><s>Following the method of BROOKMEYER and CROWLEY <ref type="bibr" target="#b13">[14]</ref>, 110 patients per therapy arm were necessary to obtain a lower 95% confidence limit of about 5 months for the median PFS in each arm.</s><s>Time-to-event data were analysed using the Kaplan-Meier method, and the log-rank test was used to compare the distributions between groups.</s><s>In addition, hazard ratios (HR) with 95% confidence intervals (CI) were estimated using the Cox proportional hazards model <ref type="bibr" target="#b14">[15]</ref>.</s><s>Secondary end-points were analysed using adequate methods.</s><s>All p-values were two-sided.</s><s>Efficacy analyses were performed on all randomised patients (intention-to-treat (ITT) basis).</s><s>Patients receiving at least one treatment cycle were qualified for safety analysis.</s><s>All statistical analyses were done with SAS (version 9.2; SAS Institute, Cary, NC, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>From November 2007 to August 2009 a total of 224 patients were randomised from 37 sites across Germany (113 to PGB and 111 to EB).</s><s>The demographic and baseline characteristics were balanced between study arms (table <ref type="table" target="#tab_0">1</ref>).</s><s>As shown in figure <ref type="figure">1</ref>, a total of 108 patients in the EB arm and 111 in the PGB arm received at least one cycle of the respective regimen.</s><s>The median number of cycles was five in the EB and five in the PGB arm.</s><s>The proportions of patients receiving at least six cycles were similar in each treatment group (EB 44.4%, PGB 46.9%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment conduct and adverse events</head><p><s>The frequency and severity of toxicity according to treatment arm and the frequency of non-cancer-related mortality are shown in tables 2 and 3, respectively.</s><s>In the EB arm, erlotinib was temporarily stopped due to severe side-effects in 38% of patients, mandating dose reductions in 24%.</s><s>In 4.6% of bevacizumab cycles, treatment had been delayed by more than 7 days.</s><s>In the PGB arm this was documented in 13% of bevacizumab cycles and in 16% of chemotherapy cycles.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Further treatment</head><p><s>Second-line and third-line treatments are summarised in table 4. Of the 108 patients treated with EB, two were still on treatment at the time of the analysis.</s><s>106 had stopped treatment; of these, 76 had stopped due to progressive disease (fig.</s><s><ref type="figure">1</ref>).</s><s>62 (57%) out of 108 patients had received a systemic second-line treatment, 44 of them a platinum-based chemotherapy.</s><s>Of the 111 patients in the PGB arm, five were still on treatment at the time of the analysis.</s><s>106 had stopped treatment; of these, 50 had stopped due to progressive disease (fig.</s><s><ref type="figure">1</ref>).</s><s>70 (63%) out of 111 patients received a systemic second-line treatment, 22 of them an EGFR target therapy and 48 a second-line chemotherapy.</s><s>The response rate was 12% for EB and 36% for PGB ( p=0.0001).</s><s>The median PFS (ITT population) was 3.5 months in the EB arm and 6.9 months in the PGB arm.</s><s>This difference was statistically significant (HR 1.85, p&lt;0.0001).</s><s>The median overall survival (ITT population) was 12.6 months in the EB arm and 17.7 months in the PGB arm, showing a statistically significant difference (HR 1.41, p=0.0409).</s><s>Kaplan-Meier estimates for PFS and overall survival in the ITT population are shown in figure <ref type="figure">2</ref>. The minimum follow-up was 2 years for each patient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EGFR mutation analysis</head><p><s>An analysis of EGFR mutation status was performed in 159 (71%) patients, 77 (69%) randomised to EB and 82 (73%) to PGB.</s><s>In 28 (13%) cases, tumour tissue was not available, and in 37 (17%) cases, paraffin blocks were insufficient for analyses.</s><s>EGFR mutations were detected in a total of 32 patients (20% of 159), 20 in the EB group and 12 in the PGB group (fig.</s><s><ref type="figure">3</ref>).</s><s>The main patient characteristics (age, smoking status, performance status and lactate dehydrogenase distribution) were in balance with the total population.</s></p><p><s>In the EGFR-mutant patient population, the response rate for EB was 25% compared with 17% for PGB.</s><s>PFS did not differ significantly, with a median of 4.2 months with EB and 4.6 months with PGB.</s><s>However, overall survival showed a trend for superior survival with EB compared to PGB (median 17.0 versus 10.0 months; HR 0.45, 95% CI 0.18-1.16;</s><s>p=0.092) (fig.</s><s><ref type="figure">4</ref>).</s><s>All of the 20 patients in the EB group received second-line chemotherapy, whereas only three out of 12 patients in the PGB group received any further treatment.</s><s>In the EGFR wild-type patient population, the response rate was 9% for EB but 39% for PGB, with a PFS of 3.5 months versus 7.1 months (HR 2.07, 95% CI 1.42-3.02;</s><s>p=0.0001) and overall survival of 10.3 months versus 18.0 months for PGB (HR 1.76, 95% CI 1.13-2.74;</s><s>p=0.011) (fig.</s><s><ref type="figure">4</ref>).</s><s>Even in advanced NSCLC, the prognostic impact of adenocarcinoma is more favourable than other histological subtypes <ref type="bibr" target="#b19">[20]</ref>.</s><s>Moreover, the allocation to and type of further treatment after disease progression might have an impact.</s><s>In TORCH, proportions of 88% (333 out of 380) in the E arm and 83% (316 out of 380) in the PG arm were documented with progression <ref type="bibr" target="#b15">[16]</ref>.</s><s>However, only 51% (194 out of 380) of E patients and 59% (226 out of 380) of PG patients started with second-line treatment.</s><s>Similarly, the second-line treatment proportions in INNOVATIONS amounted to 57% (EB) and 63% (PGB), with only 41% of EB patients starting with platinum-based combination chemotherapy after failure of first-line treatment (table <ref type="table" target="#tab_5">5</ref>).</s><s>Thus, the outcome differences between the trials are not explained by differences of allocation to further treatment.</s><s>Although in the current trial only 41% of patients in the EB arm received any platinum-based combination chemotherapy, a median survival time of 12.6 months was achieved.</s></p><p><s>Further trials with first-line EB in NS-NSCLC are summarised in table 5.</s><s>The TASK trial showed a second-line proportion of 49% after first-line EB <ref type="bibr" target="#b10">[11]</ref>.</s><s>The SAKK (Swiss Group for Clinical Cancer Research) reported on a fixed-sequence protocol with initial EB treatment, showing a higher starting proportion in second-line treatment (62 (61%) out of 101) but a substantial drop down for those receiving four cycles or more (35 (35%) out of 101) <ref type="bibr" target="#b16">[17]</ref>.</s><s>Thus, a start-with-progression treatment strategy, even with a strictly linked treatment sequence, is not effective on all progressors.</s><s>This is in accordance with the experience derived from maintenance trials after first-line chemotherapy.</s><s>These revealed in the respective observation arms a second-line treatment proportion ranging between 63% and 72% <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>.</s><s>The deterioration of performance status due to disease progression and the preference of patients were the main reasons for not proceeding to second-line chemotherapy in these trials.</s></p><p><s>Of tumours successfully analysed for EGFR mutations, 20% (32 out of 159) showed molecular alterations of exon 19 or 21, with a high proportion revealing point mutations of uncertain biological significance (18 out of 32) (fig.</s><s><ref type="figure">3</ref>).</s><s>This substantial proportion might explain the low rates of response and PFS with EB.</s><s>The trial had finished in 2009 and the EGFR mutation analysis has been conducted retrospectively; therefore, it remains unclear whether the low proportion of mutations of biological significance can be delineated from  difficulties with implementing molecular analyses.</s><s>Explorative analyses according to treatment arm showed no improvement with EB compared with PGB, in terms of PFS.</s><s>Nonetheless, stopping EB after disease progression and implementing further treatment resulted in a trend towards superior overall survival (fig.</s><s><ref type="figure">3</ref>).</s><s>However, salvage treatment was absent in 75% of cases (nine out of 12) in the PGB arm, while all patients in the EB arm received second-line chemotherapy.</s><s>The low salvage in PGB might be due to quick deterioration but this has to remain open to speculation.</s><s>The analysis is exploratory and no firm conclusions can be drawn, due to the small patient number and a substantial proportion of mutations with uncertain significance.</s><s>A subgroup analysis of the BeTa lung trial (assessing the efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced NSCLC after failure of standard first-line chemotherapy) indicated in the second-line setting in 30 EGFR-mutated patients (exons 18-21; denaturing high-performance liquid chromatography) an advantageous overall survival with EB compared with E alone <ref type="bibr" target="#b24">[25]</ref>.</s><s>In a further extension, the recently reported JO25567 trial, randomising EGFR-mutated patients (del.</s><s>19; L858R) in first-line treatment between EB and E, stated a substantial improvement of PFS with EB (median 16.0 versus 9.7 months; HR 0.54, p=0.0015) <ref type="bibr" target="#b25">[26]</ref>.</s><s>Thus, in "activating" EGFR mutations, the interference with the VEGF pathway, in addition to EGFR tyrosine kinase inhibition (TKI), might have an impact on outcome.</s><s>The concept of "early interference" has been approached in the FASTACT-2 trial by intercalating chemotherapy with first-line TKI <ref type="bibr" target="#b26">[27]</ref>.</s><s>In the context of this trial, a retrospective analysis on mutation-positive patients revealed a significant survival advantage when intercalating EGFR-TKI upfront with chemotherapy, compared with chemotherapy followed by EGFR-TKI (84% crossover rate to EGFR-TKI after chemotherapy) <ref type="bibr" target="#b26">[27]</ref>.</s></p><p><s>Allocating lung cancer patients with tumours harbouring activating EGFR mutations or EML4-ALK translocations to appropriate TKI treatment is nowadays the standard of care <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s>Molecularly determined treatment options, mandating appropriate assessment and testing, will increasingly move into clinical routine <ref type="bibr" target="#b29">[30]</ref>.</s><s>However, placement of these approaches in the treatment algorithm should be approached thoroughly.</s><s>Development and overcoming resistance will be an issue <ref type="bibr" target="#b30">[31]</ref> and conventional chemotherapy still has potential to show sustained impact.</s><s>In this regard, randomised trials in selected patients with activating EGFR mutations, comparing EGFR-TKI against chemotherapy in first-line treatment, showed no survival advantage between treatment arms, given a crossover to EGFR-TKI after failure of chemotherapy <ref type="bibr" target="#b27">[28]</ref>.</s><s>Nonetheless, recently a combined analysis of two trials comparing chemotherapy with afatinib as upfront TKI (with a 66% crossover rate to EGFR-TKI after failure of chemotherapy) revealed a substantial survival advantage for upfront TKI in cases with del.</s><s>19 but not L858R mutations <ref type="bibr" target="#b31">[32]</ref>.</s></p><p><s>In conclusion, platinum-based combination chemotherapy remains the standard of care in first-line treatment of unselected NS-NSCLC, showing most favourable survival with the addition of bevacizumab in the current trial.</s><s>Concise molecular assessment is a prerequisite to implementing molecular targeted approaches in any line of therapy.</s><s>It clearly has to be emphasised that those approaches strongly mandate appropriate testing and patient selection.</s><s>Unselected NSCLC patients should not receive TKI as a first-line treatment, as has been shown in further trials (table <ref type="table" target="#tab_5">5</ref>).</s><s>To derive the most optimal impact on outcome and mitigate resistance, complementing treatments, as well as the sequencing of treatment lines and their effect on overall survival, should be assessed properly.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1</head><label>1</label><figDesc><div><p><s>Baseline patient characteristics</s></p></div></figDesc><table><row><cell>EB arm</cell><cell>PGB arm</cell></row></table><note><p><s>Data are presented as n, mean (range) or n (%).EB: erlotinib/bevacizumab; PGB: cisplatin/gemcitabine/ bevacizumab; ECOG: Eastern Cooperative Oncology Group; ULN: upper limit of normal; EGFR: epidermal growth factor receptor.FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.</s><s>EB: erlotinib/bevacizumab; PGB: cisplatin/ gemcitabine/bevacizumab.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 2</head><label>2</label><figDesc><div><p><s>Frequency and severity of toxicity</s></p></div></figDesc><table><row><cell></cell><cell cols="2">EB arm # toxicity</cell><cell cols="2">PGB arm  ¶ toxicity</cell></row><row><cell></cell><cell>Grade 1+2</cell><cell>Grade 3-5</cell><cell>Grade 1+2</cell><cell>Grade 3-5</cell></row><row><cell>Anaemia</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell>18 (16.2)</cell><cell>7 (6.3)</cell></row><row><cell>Neutropenia</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell>7 (6.3)</cell><cell>8 (7.2)</cell></row><row><cell>Febrile neutropenia +</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell>2 (1.8)</cell></row><row><cell>Thrombocytopenia</cell><cell>0 (0)</cell><cell>0 (0)</cell><cell>18 (16.2)</cell><cell>16 (14.4)</cell></row><row><cell>Nausea/vomiting</cell><cell>19 (17.6)</cell><cell>2 (1.9)</cell><cell>52 (46.8)</cell><cell>11 (9.9)</cell></row><row><cell>Hypertension</cell><cell>15 (13.9)</cell><cell>4 (3.6)</cell><cell>12 (10.8)</cell><cell>12 (10.8)</cell></row><row><cell>Cardiac disorders</cell><cell>5 (4.6)</cell><cell>4 (3.7)</cell><cell>9 (8.1)</cell><cell>4 (3.6)</cell></row><row><cell>Thromboembolism</cell><cell>0 (0)</cell><cell>5 (4.6)</cell><cell>5 (4.5)</cell><cell>16 (14.4)</cell></row><row><cell>Rash</cell><cell>61 (56.5)</cell><cell>18 (16.7)</cell><cell>12 (10.8)</cell><cell>1 (0.9)</cell></row><row><cell>Diarrhoea</cell><cell>37 (34.3)</cell><cell>3 (2.8)</cell><cell>17 (15.3)</cell><cell>2 (1.8)</cell></row><row><cell>Fatigue</cell><cell>18 (16.7)</cell><cell>1 (0.9)</cell><cell>37 (33.3)</cell><cell>5 (4.5)</cell></row><row><cell>Dyspnoea</cell><cell>16 (14.8)</cell><cell>5 (4.6)</cell><cell>23 (20.7)</cell><cell>5 (4.5)</cell></row><row><cell>Gastrointestinal complaints</cell><cell>9 (8.3)</cell><cell>8 (7.4)</cell><cell>17 (15.3)</cell><cell>1 (0.9)</cell></row><row><cell>Infection</cell><cell>24 (22.2)</cell><cell>9 (8.3)</cell><cell>22 (19.8)</cell><cell>9 (8.1)</cell></row><row><cell>Bleeding events</cell><cell>13 (12.0)</cell><cell>2 (1.9)</cell><cell>30 (27.0)</cell><cell>1 (0.9)</cell></row><row><cell>Epistaxis</cell><cell>11 (10.2)</cell><cell>0 (0)</cell><cell>26 (23.4)</cell><cell>1 (0.9)</cell></row><row><cell>Gingival bleeding</cell><cell>3 (2.8)</cell><cell>0 (0)</cell><cell>2 (1.8)</cell><cell>0 (0)</cell></row><row><cell>Gastrointestinal haemorrhage</cell><cell>2 (1.9)</cell><cell>1 (0.9)</cell><cell>4 (3.6)</cell><cell>0 (0)</cell></row><row><cell>Pulmonary haemorrhage</cell><cell>1 (0.9)</cell><cell>1 (0.9)</cell><cell>0 (0)</cell><cell>0 (0)</cell></row></table><note><p><s>Data are presented as n (%).</s><s>EB: erlotinib/bevacizumab; PGB: cisplatin/gemcitabine/bevacizumab.</s><s># : n=108; ¶ : n=111; + : fever &gt;38.5°C and absolute neutrophil count &lt;1.0×10 9 cells•L −1 .</s><s>DOI: 10.1183/09031936.00229014</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 3</head><label>3</label><figDesc><div><p><s>Frequency of non-cancer-related mortality</s></p></div></figDesc><table><row><cell>EB arm # deaths</cell><cell>PGB arm  ¶ deaths</cell></row></table><note><p><s>#: n=108; ¶ : n=111.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 4</head><label>4</label><figDesc><div><p><s>Allocation to and type of second-and third-line treatments Epidermal growth factor receptor (EGFR) mutation analysis with Sanger sequencing, by treatment arm.</s><s>EB: erlotinib/bevacizumab; PGB: cisplatin/gemcitabine/bevacizumab; wt: wild type; mut: mutation.</s><s>Other mutations were as follows.</s><s>Exon 19, EB arm: N756H, L747F, L747P, R748K, L730P+A755P; exon 19, PGB arm: D761N, S752F, V742A.</s><s>Exon 21, EB arm: P848L, D855N, R832C, R831C, T847I, A859S; exon 21, PGB arm: P848L, D855N, L838N, E868G.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Second-line</cell><cell></cell><cell>Third-line</cell></row><row><cell></cell><cell>EB arm</cell><cell>PGB arm</cell><cell>EB arm</cell><cell>PGB arm</cell></row><row><cell>Patients</cell><cell>108</cell><cell>111</cell><cell>108</cell><cell>111</cell></row><row><cell>Radiation therapy only</cell><cell>4 (4)</cell><cell>3 (3)</cell><cell>3 (3)</cell><cell>3 (3)</cell></row><row><cell>Any systemic treatment</cell><cell>62 (57)</cell><cell>70 (63)</cell><cell>40 (37)</cell><cell>34 (31)</cell></row><row><cell>EGFR-TKI</cell><cell>3 (3)</cell><cell>22 (20)</cell><cell>3 (3)</cell><cell>11 (10)</cell></row><row><cell>Mono chemotherapy</cell><cell>15 (14)</cell><cell>36 (32)</cell><cell>30 (28)</cell><cell>20 (18)</cell></row><row><cell>Docetaxel</cell><cell>1 (1)</cell><cell>7 (6)</cell><cell>8 (7)</cell><cell>7 (6)</cell></row><row><cell>Pemetrexed</cell><cell>6 (6)</cell><cell>26 (23)</cell><cell>12 (11)</cell><cell>8 (7)</cell></row><row><cell>Gemcitabine</cell><cell>4 (4)</cell><cell>0 (0)</cell><cell>2 (2)</cell><cell>0 (0)</cell></row><row><cell>Other</cell><cell>4 (4)</cell><cell>3 (3)</cell><cell>8 (7)</cell><cell>5 (5)</cell></row><row><cell>Combination chemotherapy</cell><cell>44 (41)</cell><cell>12 (11)</cell><cell>7 (6)</cell><cell>3 (3)</cell></row><row><cell>Cisplatinum-based</cell><cell>24 (22)</cell><cell>7 (6)</cell><cell>2 (2)</cell><cell>2 (2)</cell></row><row><cell>Carboplatinum-based</cell><cell>20 (19)</cell><cell>5 (5)</cell><cell>3 (3)</cell><cell>1 (1)</cell></row></table><note><p><s>[17][18][19]sented as n or n (%).EB: erlotinib/bevacizumab; PGB: cisplatin/gemcitabine/bevacizumab; EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibition.DiscussionINNOVATIONS assessed a combination of and bevacizumab (EB) compared with cisplatin-based chemotherapy with bevacizumab in first-line treatment of unselected advanced NS-NSCLC patients, amenable to cisplatin.The combination of cisplatin, gemcitabine and bevacizumab (PGB) showed superior overall survival (HR 1.41; p=0.0409), response rate (36% versus 12%; p&lt;0.0001) and PFS (HR 1.85; p&lt;0.0001).PFS and overall survival ranged in the most favourable spans reported for combination chemotherapy and bevacizumab in NS-NSCLC[4,5,10].Similar to INNOVATIONS, an HR of 1.24 on overall survival has been derived from the TORCH (Tarceva or Chemotherapy) trial[16], comparing erlotinib (E) with cisplatin and gemcitabine (PG) in first-line treatment of unselected NSCLC patients, amenable to cisplatin.The TORCH trial protocol outlined a strictly linked second-line treatment mandating PG (E arm) and E (PG arm), while in INNOVATIONS this was recommended but not strictly mandated (table5)[17][18][19].Both trials emphasise platin-based combination chemotherapy as the standard of care in first-line treatment of unselected patients with advanced NSCLC.Even with first-line PG, TORCH patients performed similarly to those allocated to EB in INNOVATIONS and worse than those allocated to PGB (table5).</s><s>This might be due to the addition of bevacizumab in both arms of INNOVATIONS, providing 1) a treatment effect and 2) a selection effect of patients included.</s><s>It may be of importance that there was a substantial difference in inclusion patterns in terms of histology, with predominant adenocarcinoma enrolment in INNOVATIONS (89% in INNOVATIONS versus 55% in</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>TABLE 5</head><label>5</label><figDesc><div><p><s>Trials with erlotinib (E) erlotinib plus bevacizumab (EB) as first-line treatment in unselected patients with advanced nonsmall cell lung cancer (NSCLC)</s></p></div></figDesc><table><row><cell>Trial</cell><cell>Trial type</cell><cell>Histology</cell><cell>First-line</cell><cell>Second-line</cell><cell cols="2">Patients Proportion with</cell><cell>Proportion with</cell><cell>Proportion with</cell><cell>PFS</cell><cell>Overall survival</cell></row><row><cell></cell><cell></cell><cell>enrolled</cell><cell>treatment</cell><cell>treatment</cell><cell></cell><cell>documented</cell><cell>second-line</cell><cell>platinum-based CCT</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>progression</cell><cell>treatment</cell><cell>in second line</cell><cell></cell><cell></cell></row><row><cell>TORCH [16]</cell><cell>Phase III</cell><cell>NSCLC</cell><cell>PG</cell><cell>sl E</cell><cell>380</cell><cell>316 (83)</cell><cell>226 (59)</cell><cell>-</cell><cell>5.4 (4.8-6.3)</cell><cell>11.6 (10.2-13.3)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>E</cell><cell>sl PG</cell><cell>380</cell><cell>333 (88)</cell><cell>194 (51)</cell><cell>194 (51)</cell><cell>2.2 (2.1-2.4)</cell><cell>8.7 (7.4-10.5)</cell></row><row><cell>INNOVATIONS</cell><cell>Phase II,</cell><cell>NS-NSCLC</cell><cell>PGB</cell><cell>rec. E</cell><cell>113</cell><cell>100 (88)</cell><cell>70 (63)</cell><cell>12 (11)</cell><cell>6.9 (5.6-8.3)</cell><cell>17.7 (12.1-21.6)</cell></row><row><cell>(current study)</cell><cell>randomised</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>EB</cell><cell>rec. PG</cell><cell>111</cell><cell>101 (91)</cell><cell>62 (57)</cell><cell>44 (41)</cell><cell>3.5 (2.8-4.1)</cell><cell>12.6 (10.2-16.2)</cell></row><row><cell>TASK [11]</cell><cell>Phase II,</cell><cell>NS-NSCLC</cell><cell>CB</cell><cell>Open</cell><cell>63</cell><cell>-</cell><cell>-(66)</cell><cell>-</cell><cell>5.8 (4.8-NR)</cell><cell>NR (-)</cell></row><row><cell></cell><cell>randomised</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>EB</cell><cell>Open</cell><cell>61</cell><cell>-</cell><cell>-(49)</cell><cell>-</cell><cell>4.3 (4.0-5.8)</cell><cell>16.4 (-)</cell></row><row><cell>SAKK [17]</cell><cell>Phase II</cell><cell>NS-NSCLC</cell><cell>EB</cell><cell>sl PG</cell><cell>101</cell><cell>-</cell><cell>62 (61)</cell><cell>62 (61) #</cell><cell>4.1 (2.9-5.5)</cell><cell>14.1 (10.7-19.0)</cell></row><row><cell>AKERLEY [18]</cell><cell>Phase II</cell><cell>NS-NSCLC</cell><cell>EB</cell><cell>Open</cell><cell>50</cell><cell>45 (90)</cell><cell>28 (56)</cell><cell>26 (52)</cell><cell>3.9 (3.3-4.4)</cell><cell>11.6 (8.1-13.4)</cell></row><row><cell>DINGEMANS [19]</cell><cell>Phase II</cell><cell>NS-NSCLC</cell><cell>EB</cell><cell>Open</cell><cell>47</cell><cell>35 (74)</cell><cell>-</cell><cell>-</cell><cell>3.8 (2.3-5.4)</cell><cell>6.9 (5.5-8.4)</cell></row></table><note><p><s>Data are presented as n, n (%) or median (95% CI).</s><s>CCT: combination chemotherapy after progression; PFS: progression-free survival; TORCH: Tarceva or Chemotherapy; SAKK: Swiss Group for Clinical Cancer Research; PG: cisplatin/gemcitabine; sl: strictly linked; NS: nonsquamous; PGB: cisplatin/gemcitabine/bevacizumab; rec.: recommended; CB: chemotherapy (cislatin/gemcitabine or carboplatin/paclitaxel)/bevacizumab; -: not reported; NR: not reached.</s><s># : 35 (35%) patients receiving at least four cycles.</s><s>DOI: 10.1183/09031936.00229014</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">DOI: 10.1183/09031936.00229014</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Azzoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Temin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Aliff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3825" to="3831" />
			<date type="published" when="2009">2011. 2009. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Belani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="92" to="98" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3543" to="3551" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sandler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="2542" to="2550" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Crinò</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dansin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garrido</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="733" to="740" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Mansfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Akagi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1133" to="1140" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Onn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Isobe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="471" to="483" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Herbst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mininberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2544" to="2555" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ardizzoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tiseo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="847" to="857" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL</title>
		<author>
			<persName><forename type="first">M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zatloukal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1227" to="1234" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><surname>Tsao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="276" to="281" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies</title>
		<author>
			<persName><forename type="first">A</forename><surname>Warth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Penzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brandt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">460</biblScope>
			<biblScope unit="page" from="407" to="414" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">EGFR mutation detection in NSCLC -assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC</title>
		<author>
			<persName><forename type="first">R</forename><surname>Penzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">458</biblScope>
			<biblScope unit="page" from="95" to="98" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A confidence interval for the median survival time</title>
		<author>
			<persName><forename type="first">R</forename><surname>Brookmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crowley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="29" to="41" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Regression models and life-tables</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Cox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J R Stat Soc Series B Stat Methodol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="187" to="220" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gridelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ciardiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gallo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3002" to="3011" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zappa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Droege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Betticher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="239" to="244" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Akerley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="307" to="311" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Dingemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>De Langen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Van Den Boogaart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="559" to="566" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program</title>
		<author>
			<persName><forename type="first">K</forename><surname>Cetin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Ettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Hei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="139" to="148" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Fidias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Dakhil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Lyss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="591" to="598" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Paz-Ares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Marinis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dediu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="247" to="255" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brodowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zielinski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="1432" to="1440" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Cappuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Stelmakh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="521" to="529" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Herbst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ansari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bustin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="1846" to="1854" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Seto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1236" to="1244" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Thongprasert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="777" to="786" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Keedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Temin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Somerfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2121" to="2127" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="2385" to="2394" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies</title>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Mack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1039" to="1049" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">E</forename><surname>Maruvka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Michor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1070" to="1080" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Overall survival (OS) in patients ( pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)) comparing afatinib with chemotherapy (CT)</title>
		<author>
			<persName><forename type="first">Jch</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Sequist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Schuler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl. 15, 8004</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
